Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine Therapy

Trial Profile

Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Letrozole (Primary) ; Palbociclib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms INGE-B
  • Sponsors iOMEDICO AG
  • Most Recent Events

    • 12 Apr 2017 Planned number of patients changed from 120 to 360.
    • 12 Apr 2017 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.
    • 12 Apr 2017 Planned primary completion date changed from 1 Sep 2021 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top